Uniogen’s unique glycovariant immunoassay technology is based on nanoparticles coated with carbohydrate group-specific binders at a high density, translating to an improved sensitivity and specificity compared to conventional assays. We’re currently developing our first proprietary test for the early detection of ovarian cancer and hold patents for detection of a variety of cancer types.

GenomEra® CDX system by Uniogen is a powerful tool for running molecular diagnostics routinely and cost-efficiently—with zero compromises in assay reliability or quality. Our current offering of CE-marked GenomEra IVD tests covers ten different assay kits for the detection of different infectious agents, including SARS-CoV-2.

Upcon® is a first-of-a-kind labeling technology utilizing photostable upconverting nanoparticles that allow measurement without photobleaching, self-quenching or autofluorescence, and bright luminescence with discrete emission bands —even through tissue and in whole blood. Upcon is applicable to quantitative lateral flow tests, bioaffinity assays, microscopy, and imaging.